Index
Pharmacological Reviews
Volume 40
1988

Acenocoumarol, binding parameters, alpha-1-acid glycoprotein (table), 17, 31
Acepromazine, binding to alpha-1-acid glycoprotein (table), 18
Acetorphan, gastric acid secretion in cat, 141
Acetylcholine
  opioid effects, 140
  opioid interactions, 134
  release, decrease in gastric acid secretion, rat, 140
Acetylcholinesterase
Achalasia, hypertrophic pyloric stenosis and, opioids, motility, 136
Acidosis, alpha-1-acid glycoprotein levels (table), 9
Adenosine
  actions, 66
  effects of inflammatory mediators in asthma (table), 52
  origin, 66
  receptors, 66
  role in asthma, 66
Adenosine triphosphatase, sarclemmal calcium pump, 207
Aging
  albumin and alpha-1-acid glycoprotein levels (table), 12
  alpha-1-acid glycoprotein binding ratio (table), 20
  alpha-1-acid glycoprotein levels (table), 9
  3-methoxytyramine measurements, dopamine release, neurons, 172
  young and aged rats, dopamine and metabolites (table), 173
Airway
  bradykinin, 65
  bronchial hyper-responsiveness (fig.), 58
  effect on nerves, bradykinin, 65
  effects of serotonin, 70
  inflammatory cells, 68
  inflammatory mediators and asthma, 53
  lipoxygenase products, 59
  secretions, 66, 69, 62, 65, 68
  inflammatory mediators, asthma, 53
  smooth muscle, 62, 65, 67
  inflammatory mediators, 56
  vascular effects, 62, 65, 68
Albumin
  alpha-1-acid glycoprotein and
    drug binding, 1
  healthy people and patients (table), 11
  drug interactions, alpha-1-acid glycoprotein, 16
Alcohol use, alpha-1-acid glycoprotein levels (table), 9
Aldehyde dehydrogenase, metabolic routes for dopamine degradation (fig.), 166
Alfentanil, binding parameters, alpha-1-acid glycoprotein (table), 17, 24
Allergy
  alpha-1-acid glycoprotein levels (table), 9
  biological activities, alpha-1-acid glycoproteins, 16
Alpha-1-acid glycoprotein
  acidic drug binding, 23
  acidic drug binding (table), 31
  acute phase protein, 9
  basic and neutral drug binding, 23
  binding parameters (table), 24
  binding ratio and concentration, drugs, disease states (table), 19
  biological functions, 9
  drug binding in health and disease, 1
  drug interactions, 16
  factors influencing drug binding, 32
  isoniazid/structure/physical-chemical properties, 2
  levels in human plasma during disease (table), 9
  microheterogeneity, 5
  microheterogeneous studies (table), 5
  molecular weight, 7
  nature and number of binding sites, 31
  structure and physical-chemical properties, 7
  survey of binding studies (table), 17
  survey of history of studies (table), 2
  survey of reported molecular weights (table), 4
  surveys of names and variants (table), 3
Alprenolol
  alpha-1-acid glycoprotein binding ratio (table), 19
  binding parameters, alpha-1-acid glycoprotein (table), 17, 24
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Altar, C. Anthony See Wood and Altar, 163
Amino acids, molecular biology of cytochrome P-450s (fig.), 259
Aminooxyacetic acid, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Amitriptyline
  alpha-1-acid glycoprotein binding ratio (table), 19
  binding parameters, alpha-1-acid glycoprotein (table), 17, 24
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Amphenazole, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Amphetamine
  actions on accumulation of 3-methoxytyramine (table), 170
  effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
AMPT, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Apoporphine
  actions on accumulation of 3-methoxytyramine (table), 170
  effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Aprindine, binding parameters, alpha-1-acid glycoprotein (table), 17, 24
Arachidonic acid
  alpha-1-adrenergic receptor-stimulated release (fig.), 93
  cytochrome P-450 metabolism, 229
  metabolism by extrahepatic cytochrome P-450 monooxygenase, 232
  metabolism by fatty acid hydrolases, 232
  metabolism by hepatic cytochrome P-450 monooxygenase, 231
  metabolism of monoxygenase metabolites, 234
  monohydroxy metabolite formation (fig.), 237
  stereochecmistry, 232
  transformations of, cytochrome P-450 monooxygenase metabolism
INDEX

Doxepin
binding parameters, alpha-1-acid glycoprotein (table), 26
binding to alpha-1-acid glycoprotein (table), 17

Eicosanoids
bio-synthesis of (table), 231
“epoxygenase”-derived, cytochrome P-450 metabolism, arachidonic acid, 229
metabolism by monooxygenase enzymes, 234

Electrolytes
absorption, 151
secretion, role of opioids, 146

Endocrine systems, arachidonic acid metabolism, 235
Eosinophils, inflammatory mediators and asthma, 50

Epilepsy
albumin and alpha-1-acid glycoprotein levels (table), 12
alpha-1-acid glycoprotein levels (table), 9
alpha-1-acid glycoprotein binding ratio (table), 19

Epinephrine, effect of nonhydrolyzable GTP analog (fig.), 91

Epithelial cells, inflammatory mediators and asthma, 50

Epithelium, corneal, arachidonic acid metabolism, 236

Ergocornine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Erythromycin
alpha-1-acid glycoprotein binding ratio (table), 19
binding parameters, alpha-1-acid glycoprotein (table), 26
binding to alpha-1-acid glycoprotein (table), 17
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Estradiol, binding to alpha-1-acid glycoprotein (table), 17

Ethanol, actions on accumulation of 3-methoxytyramine (table), 170

Ethylketazocine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176

Etidocaine
binding parameters, alpha-1-acid glycoprotein (table), 17, 26
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Etophyrine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Eucaryote cells, stable expression of cytochrome P-450, 262

Eunice, possible biological significance, 137

Fatty acid hydrolases, metabolism of arachidonic acid, 232

Felodipine, effect on contractile response, norepinephrine (fig.), 98

Fentanyl, binding parameters, alpha-1-acid glycoprotein (table), 17, 26

Fentanyl, factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Fitzpatrick, F. A. and R. C. Murphy. Cytochrome P-450 metabolism of arachidonic acid: Formation and biological actions of “Epoxygenase”-derived eicosanoids, 229

Flumazenil, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Fluphenazine
actions on accumulation of 3-methoxytyramine (table), 170
binding parameters, alpha-1-acid glycoprotein (table), 17, 26

Folic acid, binding parameters, alpha-1-acid glycoprotein (table), 31

Fozzard, Harry A. See January and Fozzard, 219

GABAergics, modulation of nigrostriatal pathway, 180

Gastric acid, secretion, role of opioids, 139

Gastrin
potential influences, 143
release, 144

Gastrointestinal tract, tumors and inflammation, 137

Gastrointestinal sphincters
motility, various species, 130
species differences, 133

GBL
actions on accumulation of 3-methoxytyramine (table), 170
effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Gene
anomalous P-450 gene transcripts, pseudogenes, 273
conversion events, cytochrome P-450s, 259
detection of mutant genes, cytochrome P-450 (fig.), 276
mutant, cytochrome P-450, 275
P450 subfamily in two species (fig.), 260
tissue-specific expression, cytochrome P-450, 269

Genetic factor
albumin and alpha-1-acid glycoprotein levels (table), 12
alpha-1-acid glycoprotein levels (table), 9

Glioma, alpha-1-acid glycoprotein levels (table), 9

Gonzalez, Frank J. The molecular biology of cytochrome P450s, 243

guanine nucleotide regulatory proteins
alpha 1-adrenergic receptor subtypes, 91
potency of epinephrine (fig.), 91

Gut
distribution of opioid peptides, 123
stress-induced opioid dependence, 137

HA-966, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Haloperidol
actions on accumulation of 3-methoxytyramine (table), 170
actions on dihydroxyphenylacetic acid, 3-methoxytyramine levels (table), 177
binding parameters, alpha-1-acid glycoprotein (table), 17, 26
effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Heart
charge-carrying mechanism for i_in, membrane channel, exchange pump current, 221
delayed afterpolarizations, 219
calcium, clinical arrhythmias, 224
early afterpolarizations, 223
explanation of terms, inotropic mechanisms, calcium mobilization (table), 191
inotropic mechanisms, calcium mobilization, 189
steriologv, cardiac cell components (table), 208
ventricular and atrial muscle, calcium pump, sarcoplasmic reticulum, 208
ventricular cells, control sites, contraction-related calcium, 190
HeLa cells, biological activities, alpha-1-acid glycoprotein, 15

Heme
-binding cysteine-containing peptide, 258
effect on P-450 induction, 267

Hemodialysis
albumin and alpha-1-acid glycoprotein levels (table), 12
alpha-1-acid glycoprotein levels (table), 9
Hepatitis
albumin and alpha-1-acid glycoprotein levels (table), 12
alpha-1-acid glycoprotein levels (table), 9
Hernia, repair, albumin and alpha-1-acid glycoprotein levels (table), 14
Hip, replacements, albumin and alpha-1-acid glycoprotein levels (table), 14
Hirschsprung’s disease, opioids, control, gastrointestinal motility, 136
Histamine
antihistamines, 54
biological activities, alpha-1-acid glycoprotein, 15
effects (table), 52
inflammatory mediators and asthma, 52
opioid effects, 140
potential influences, 143
receptors, 52
release in asthma, 54
Homovanillic acid
actions of pargyline (fig.), 169
dopamine and metabolites, aging (table), 173
dynamics (table), 168
stimulation frequency, dopamine, substantia nigra (fig.), 171
striatal dopamine metabolism (fig.), 171
Hydroxyeicosatetraenoic acid
absolute configuration (table), 232
cytochrome P-450 metabolism, arachidonic acid, 229
"epoxygenase"-derived, 234
mechanism of action, 238
monooxygenase biosynthesis (table), 232
stereoisomers of (fig.), 233
Hyperlipidemia, alpha-1-acid glycoprotein levels (table), 9
Hyperlipoproteinemia, alpha-1-acid glycoprotein levels (table), 9
Hypertension, alpha-1-acid glycoprotein levels in plasma (table), 9
Hypoaalbuminemia
albumin and alpha-1-acid glycoprotein levels (table), 12
alpha-1-acid glycoprotein binding ratio (table), 20
Hypolipidemic drugs, -inducible P-450 genes, 266
Imidazolines, alpha-1-adrenergic receptor subtypes, 102
Imipramine
actions on accumulation of 3-methoxytyramine (table), 170
alpha-1-acid glycoprotein binding ratio (table), 19
binding parameters, alpha-1-acid glycoprotein (table), 18, 26
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Immunosuppression, biological activities, alpha-1-acid glycoprotein, 15
Indomethacin, binding parameters, alpha-1-acid glycoprotein (table), 31
Indoramin, complex behavior of oxymetazoline (fig.), 105
Infection
albumin and alpha-1-acid glycoprotein levels (table), 13
bacterial
albumin and alpha-1-acid glycoprotein levels (table), 13
alpha-1-acid glycoprotein levels (table), 9
viral, albumin and alpha-1-acid glycoprotein levels (table), 13
Inflammation
albumin and alpha-1-acid glycoprotein levels (table), 13
alpha-1-acid glycoprotein levels (table), 9
Inflammatory mediators
antagonists, 51
asthma and, 49
explanation of terms (table), 50
different cells in asthma process (fig.), 50
effects on target cells (fig.), 51
interactions, 51
receptors, 51
Inositol phosphate
alpha-1-acid glycoprotein binding ratio (table), 20
alpha-1-adrenergic receptor-stimulated release, arachidonic acid (fig.), 93
alpha-1-adrenergic receptor subtypes, cell calcium sources, 87
dose response relationship, Bay K 8644 (fig.), 92
Inositol phospholipid
relationship to metabolism and calcium influx, 110
signal transduction, 89
Intestine, large
motility, various species, 130
opioid effects, different species, 129
opioids, control, gastrointestinal motility, 150
species differences, opioids, gastrointestinal motility, 133
Intestine, small
comparison of motility, rabbit and rat, cat and dog, 129
guinea pig, role of opioids, gastrointestinal motility, 125
motility, various species, 130
role of opioids in control of water, electrolyte secretion, absorption, 146
Itanozone, binding parameters, alpha-1-acid glycoprotein (table), 31
Janssen, Lambert H. M. See Kremer, Wilting, and Janssen, 1
January, Craig T. and Harry A. Fozard. Delayed afterdepolarizations in heart muscle, mechanisms and relevance, 219
Ketamine
binding parameters, alpha-1-acid glycoprotein (table), 17, 27
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Kidney
albumin and alpha-1-acid glycoprotein levels (table), 14
alpha-1-acid glycoprotein binding ratio (table), 19, 20
chronic failure, alpha-1-acid glycoprotein levels (table), 9
COS cell transient expression vector, cytochrome P-450, 261
Kojic acid, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Kremer, Josephina M. H., Jaap Wilting, and Lambert H. M. Janssen. Drug binding to human alpha-1-acid glycoprotein in health and disease, 1
Kromer, Wolfgang. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion, 121
Kyorophas, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176
Leukotrienes, effects of inflammatory mediators in asthma (table), 52
Lidoaocene
alpha-1-acid glycoprotein binding ratio (table), 19, 20
binding parameters, alpha-1-acid glycoprotein (table), 17, 27
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Lipoproteins, drug interactions, alpha-1-acid glycoprotein, 16
Lipoxygenase, transformation of epoxideicosatrienoic acids, 234
Lipoxygenase products receptor, 58
synthesis and metabolism, 57
Liver
cirrhosis
albumin and alpha-1-acid glycoprotein levels (table), 12
alpha-1-glycoprotein levels (table), 9
disease, alpha-1-acid glycoprotein binding ratio (table), 21
Lofentanil, factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Loxapine, binding parameters, alpha-1-acid glycoprotein (table), 18, 27
Macrophages, inflammatory mediators and asthma, 50
Mast cells, inflammatory mediators and asthma, 49
Mephenyline
alpha-1-acid glycoprotein binding ratio (table), 20
INDEX

binding to alpha-1-acid glycoprotein (table), 17
Mepерidine, binding parameters, alpha-1-acid glycoprotein (table), 27
Metoprolol, binding parameters, alpha-1-acid glycoprotein (table), 27
Methadone
alpha-1-acid glycoprotein binding ratio (table), 20
binding parameters, alpha-1-acid glycoprotein (table), 17, 27
effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Methamphetamine, actions on accumulation of 3-methoxytyramine (table), 170
Methotrexate, binding parameters, alpha-1-acid glycoprotein (table), 31
3-Methoxytyramine
actions of pargyline (fig.), 169
dopamine and metabolites, aging (table), 173
dopamine metabolism and release, uncoupled processes (table), 174
dynamics (table), 168
measurements
dopamine release, neurons, 163
summary, known limitations, 182
profile of actions of morphine (table), 181
stimulation frequency, dopamine, substantia nigra (fig.), 171
3-Methylcholantherene, regulation of cytochrome P-450 gene expression, 282
Methylphenidate, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
3-Methoxytyramine accumulation versus steady-state measurements, 168
analytical methods, 168
biochemistry, 166
dynamics, 167
fractional rate constants, microwave-irradiated rat brain (table), 167
linear accumulation (table), 168
Metoclopramide, actions on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 177
Metocurine, binding to alpha-1-acid glycoprotein (table), 17
Metoprolol, binding to alpha-1-acid glycoprotein (table), 17
Mianserin
binding parameters, alpha-1-acid glycoprotein (table), 27
binding to alpha-1-acid glycoprotein (table), 18
Minaprine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Minnenman, Kenneth P. α1-Adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+, 87
Molindone, actions on accumulation of 3-methoxytyramine (table), 170
Monoamine oxidase
metabolic routes for dopamine degradation (fig.), 166
working model of dopamine metabolism (fig.), 166
Morphine
effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
profile of actions, dihydroxyphenylacetic acid, 3-methoxytyramine levels (table), 181
Motilin, opioid interactions, 134
MR 2034, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176
Multiple sclerosis, alpha-1-acid glycoprotein levels (table), 9
Murphy, R. C. See Fitzpatrick and Murphy, 229
Muscinol, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Muscle
aftercontractions, 197
contraction, depolarization-induced, calcium, 199
early contraction component, ryanodine, frequency-dependent effect (fig.), 203
effect of calcium load on contraction, 199
excitation-contraction coupling, 190
heart, delayed afterpolarizations, 219
late and early rested state contractions, 192
oscillatory afterpotentials, 198
rested state contractions, effects, nifedipine, 192
smooth
contractions, α1-adrenergic receptor subtypes, 96
opioid effects, 135
phasic versus tonic, 97
two-component contractions, 194
two-component contractions (table), 195
Myocardial infarction
albumin and alpha-1-acid glycoprotein levels (table), 13
alpha-1-acid glycoprotein binding ratio (table), 19, 20
alpha-1-acid glycoprotein levels (table), 9
Myofibrils, stereology, cardiac cell components (table), 208
Naloxone
effect, absence of exogenous opioids, 143, 144, 150
effect in absence of exogenous opioids, relation, endogenous opioids, 131
effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176
role of opioids, electrolyte secretion, guinea pig, 146
Naproxen, binding to alpha-1-acid glycoprotein (table), 17
Neonates, bacterial infection, albumin and alpha-1-acid glycoprotein levels (table), 11
Nephrotic disease, alpha-1-acid glycoprotein levels (table), 9
Neural
effects, inflammatory mediators and asthma, 53
Neurokinin A, effects of inflammatory mediators in asthma (table), 52
Neuroleptics
atypical, dihydroxyphenylacetic acid, 3-methoxytyramine levels (table), 177
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Neurons, dopamine release, measurements, 3-methoxytyramine, 163
Neuropeptides
sensory, 66
airway effects, 67
origin, 67
receptors, 67
Neurotensin, opioid interactions, 134
Neuromodulators, neuromodulators and, opioid interactions, 134
Neutrophils, inflammatory mediators and asthma, 50
Nicergoline, binding parameters, alpha-1-acid glycoprotein (table), 17, 27
Nifedipine
effect on norepinephrine-induced contractions, 111
effects on rested state contractions, 192
signal transduction, α1-adrenergic receptors (fig.), 112
Nitrazepam, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Nomifensine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176
Noradrenaline
agonists in rat vas deferens (fig.), 106
complex behavior of oxymetazoline (fig.), 105
effect of felodipine (fig.), 98
- induced contractions, rabbit arteries (fig.), 103
- induced contractions in rat vas deferens (fig.), 109
signal transduction, α1-adrenergic receptors (fig.), 112
Noradrenaline
alpha-1-acid glycoprotein binding ratio (table), 20
binding parameters, alpha-1-acid glycoprotein (table), 18, 28
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Norisomelitine
alpha-1-acid glycoprotein binding ratio (table), 21
binding to alpha-1-acid glycoprotein (table), 18
Obesity
  albumin and alpha-1-acid glycoprotein levels (table), 13
  alpha-1-acid glycoprotein binding ratio (table), 20
  alpha-1-acid glycoprotein levels (table), 9

Opiates, opioid peptides and, 181
Opioids
  antagonists, absence, exogenous opioids, 141
  antiserotonergic effect, 147
  control of intestinal water, electrolyte secretion, absorption, 146
dual effects, man and monkey, 143
effect of naloxone, 131
  endogenous and exogenous, control, gastrointestinal motility and secretion, 123
exogenous, absence of, naloxone effect, 143
inhibition of stimulated acid secretion, 142
peripheral versus central effects, 141
role in gastric acid secretion, 139
Oxotremorine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176

Oxazepam
  binding parameters, alpha-1-acid glycoprotein (table), 17, 28
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Oxygen radicals
  effects of inflammatory mediators in asthma (table), 52
  inflammatory mediators and asthma, 71

Oxytremorine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176

Oxymetazoline, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176

Oxymetazoline, complex behavior (fig.), 105

Page, Clive P. See Barnes, Chung, and Page, 49

Pain
  chronic
    albumin and alpha-1-acid glycoprotein levels (table), 13
    alpha-1-acid glycoprotein levels (table), 9
  Pancreas, epoxideicosatrienoic acid, hormone release, 235
  Pancreatitis, albumin and alpha-1-acid glycoprotein levels (table), 13

Pargyline
  actions on 3-methyltransferase (fig.), 169
  effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
  linear accumulations of 3-methyltransferase (fig.), 168
  young and aged rats, dopamine and metabolites (table), 173

PCR 2362
  binding parameters, alpha-1-acid glycoprotein (table), 28
  binding to alpha-1-acid glycoprotein (table), 17

PEA, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Pentazocine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Perazine
  alpha-1-acid glycoprotein binding ratio (table), 20
  binding parameters, alpha-1-acid glycoprotein (table), 18, 28

Peristalsis
  contribution of opioids, 126
  opioid tolerance/dependence, 127

Perlapine, actions on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 177

Perphenazine, binding parameters, alpha-1-acid glycoprotein (table), 18, 28

Phenacetae, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Phencyclidine
  binding parameters, alpha-1-acid glycoprotein (table), 17, 28
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Phenethyamines, alpha-1-adrenergic receptor subtypes, 102

Phenobarbital
  binding parameters, alpha-1-acid glycoprotein (table), 18, 31
- inducible P-450 genes, 265

Phenothiazine, binding parameters, alpha-1-acid glycoprotein (table), 18, 28

Phenytoin, binding parameters, alpha-1-acid glycoprotein (table), 17, 31

Phosphodiesterase inhibitors, cyclic AMP and, 195

Pindolol
  binding parameters, alpha-1-acid glycoprotein (table), 17, 28, 29
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Piribedil, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Plasma, drug binding, alpha-1-acid glycoprotein, 16

Plasmalemma, stereology, cardiac cell components (table), 208

Platelet-activating factor
  airway effects, 62
  antagonists, 64
  bronchial hyper-responsiveness, 63
  bronchial hyper-responsiveness (fig.), 58
  effects of inflammatory mediators in asthma (table), 52
  inflammatory cell activation, 63
  inflammatory mediators and asthma, 60
  metabolism, 61
  origin, 60
  receptors, 61

Platelets
  aggregation, biological activities, alpha-1-acid glycoprotein, 15
  arachidonic acid metabolism, 236
  inflammatory mediators and asthma, 50
  inhibition of aggregation, 237
  POB, actions on accumulation of 3-methoxytyramine (table), 170

Polymorphisms
  debrisoquinase 4-hydroxylation, cytochrome P-450, 275
  P-450 expression, 272

Potassium
  dependence, inotropic effectiveness (fig.), 207
  influence, calcium stored in release compartments, 200

Prazosin
  alpha-1-acid glycoprotein binding ratio (table), 20
  binding parameters, alpha-1-acid glycoprotein (table), 17, 29
  heterogeneity in antagonist competition (fig.), 108
  yohimbine and, blocking, alpha-1-adrenergic receptor (fig.), 107

Prednisolone, alpha-1-acid glycoprotein binding ratio (table), 20

Pregnancy
  albumin and alpha-1-acid glycoprotein levels (table), 13
  alpha-1-acid glycoprotein levels (table), 9
  alpha-1-acid glycoprotein binding ratio (table), 19, 20
  Probenecid, binding parameters, alpha-1-acid glycoprotein (table), 31
  Pregabide, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175

Progesterone
  binding parameters, alpha-1-acid glycoprotein (table), 17, 29
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Propranolol
  actions on accumulation of 3-methoxytyramine (table), 170
  alpha-1-acid glycoprotein binding ratio (table), 20, 21
  binding parameters, alpha-1-acid glycoprotein (table), 17, 29
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Prostaglandins
  effects of inflammatory mediators in asthma (table), 52
  opioid interactions, 134

Protriptylamine, binding to alpha-1-acid glycoprotein (table), 18
INDEX

albumin and alpha-1-acid glycoprotein levels (table), 14
alpha-1-acid glycoprotein binding ratio (table), 20
alpha-1-acid glycoprotein levels (table), 9
Sodium, -calcium exchange, cardiac inotropic mechanisms, 206
Somatostatin
potential influences, 143
release in man, 144
Species differences, opioids, control, gastrointestinal motility, 133, 151
Spleen, effect of nifedipine (fig.), 111
Steroids, -inducible P-450 genes, 266
Stomach
control of gastric acid secretion, opioids, 139
distribution of opioid peptides, 123
gastrointestinal motility, various species, 130
Stress, alpha-1-acid glycoprotein levels (table), 9
Substance P
effects of inflammatory mediators in asthma (table), 52
opioid interactions, 134
Sufentanil, factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Sulfipyrazone, binding parameters, alpha-1-acid glycoprotein (table), 31
Sulpiride, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Surgery, alpha-1-acid glycoprotein levels (table), 9
Systemic lupus erythematosus, albumin and alpha-1-acid glycoprotein levels (table), 15
T cells, biological activities, alpha-1-acid glycoprotein, 15
Testosterone, binding to alpha-1-acid glycoprotein (table), 17
2,3,7,8-Tetrachlorodibenzoparadioxin, regulation of cytochrome P-450 gene expression, 262
Thioridazine
binding parameters, alpha-1-acid glycoprotein (table), 18, 30
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Thiothixene, binding parameters, alpha-1-acid glycoprotein (table), 18, 30
THIP, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Thromboxane, effects of inflammatory mediators in asthma (table), 52
Ticlopidine, binding parameters, alpha-1-acid glycoprotein (table), 17, 30
Timolol, binding parameters, alpha-1-acid glycoprotein (table), 17, 30
Tolmetin, binding parameters, alpha-1-acid glycoprotein (table), 31
Trauma
albumin and alpha-1-acid glycoprotein levels (table), 14
alpha-1-acid glycoprotein levels (table), 9
alpha-1-acid glycoprotein binding ratio (table), 19, 20, 21
Triazolam
alpha-1-acid glycoprotein binding ratio (table), 21
binding parameters, alpha-1-acid glycoprotein (table), 18, 30
Trifluoperazine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176
Trifluoperazine, binding parameters, alpha-1-acid glycoprotein (table), 18, 30
Tropolone, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
d-Tubocurarine, binding to alpha-1-acid glycoprotein (table), 17
U-50488H, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 176
Ulceration
conditions in man, 145
gastroduodenal, potential opioid mechanisms, 144
Ulcerative colitis
albumin and alpha-1-acid glycoprotein levels (table), 12

Psychiatric patients, albumin and alpha-1-acid glycoprotein levels (table), 12
Pylonephritis
albumin and alpha-1-acid glycoprotein levels (table), 14
alpha-1-acid glycoprotein levels (table), 9
Pyloric stenosis, hypertrophic, opioids, motility, 136
Quinidine
alpha-1-acid glycoprotein binding ratio (table), 21
binding parameters, alpha-1-acid glycoprotein (table), 17, 30
factors influencing drug binding, alpha-1-acid glycoprotein (table), 33
Quipazine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Receptors
adenosine, inflammatory mediators, asthma, 66
α1-adrenergic
classification of (table), 89
inositol phosphates, cell calcium sources, 87
microenvironment, 103
signal transduction, 91
signal transduction (fig.), 112
subtypes, 88, 100
bradykinin, inflammatory mediators, asthma, 65
cyclooxygenase products, 55
histamine, inflammatory mediators, asthma, 52
lipoxygenase products, inflammatory mediators, 58
mediator, target cell effects, 51
opioid, different types, 128, 141, 143, 147
PCP, agonists, 179
platelet-activating factor, 61
Reiter, Melchior. Calcium mobilization and cardiac inotropic mechanisms, 189
Renal systems, arachidonic acid metabolism, 236
Reserpine, effects on dihydroxyphenylacetic acid, 3-methoxytyramine steady-state levels (table), 175
Respiratory disease, albumin and alpha-1-acid glycoprotein levels (table), 13
Reticular acid, binding parameters, alpha-1-acid glycoprotein (table), 31
Rimcazole, actions on accumulation of 3-methoxytyramine (table), 170
R-PIA, actions on accumulation of 3-methoxytyramine (table), 170
Ryanodine, frequency-dependent effect, early contraction component (fig.), 203
Sarcolemma, calcium pump, 207
Sarcoplasmic reticulum
calcium release, 220
relation to calcium pump, ventricular and atrial muscle, 208
SCH 23390, actions on accumulation of 3-methoxytyramine (table), 170
Schizophrenia, alpha-1-acid glycoprotein binding ratio (table), 20
Septicemia, albumin and alpha-1-acid glycoprotein levels (table), 14
Serotonin
airway effects, 70
effects of inflammatory mediators in asthma (table), 52
opioid interactions, 134
origin, 70
receptors, 70
Setoperone, actions on dihydroxyphenylacetic acid, 3-methoxytyramine levels (table), 177
Sex
alpha-1-acid glycoprotein levels (table), 9
imprinting and gene expression, cytochrome P-450, 267
-specific gene suppression, 269
Smoking
INDEX

alpha-1-acid glycoprotein levels (table), 9
opioids, control, gastrointestinal motility, 136
Uremia, albumin and alpha-1-acid glycoprotein levels (table), 14
Uremic disease, alpha-1-acid glycoprotein levels (table), 9

Vaccinia, virus vector, cytochrome P-450, 261
Vascular effects
  inflammatory mediators and asthma, 53
  lipoxygenase products, inflammatory mediators, 59
Vasculitis, albumin and alpha-1-acid glycoprotein levels (table), 14
Vas deferens, effect of nifedipine (fig.), 111
Vasoactive intestinal peptide, opioid interactions, 134
Verapamil
  alpha-1-acid glycoprotein binding ratio (table), 21
  binding to alpha-1-acid glycoprotein (table), 17
  factors influencing drug binding, alpha-1-acid glycoprotein (table), 33

Vitamin B12, binding to alpha-1-acid glycoprotein (table), 18
Warfarin, binding parameters, alpha-1-acid glycoprotein (table), 17, 31
Wood, Paul L. and C. Anthony Altar. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: Utility of methoxytyramine measurements, 163
Wound healing, alpha-1-acid glycoprotein levels (table), 9
Yeast, expression vectors, cytochrome P-450s, 260
Yohimbine, prazosin and, blocking, α1-adrenergic receptor (fig.), 107
Zimelidine
  alpha-1-acid glycoprotein binding ratio (table), 21
  binding to alpha-1-acid glycoprotein (table), 18